论医疗机构的药品缺陷责任——对《侵权责任法》第五十九条之检讨  

Study on medical institutions' drug defects liability:reviewing the article 59 of Tort Liability Law

作　　者：徐喜荣[1] Xu Xirong(Guangzhou Medical University Department of Law, Guangzhou 511436, China)

机构地区：[1]广州医科大学法学系,广州511436

出　　处：《中国卫生法制》2016年第6期12-17,共6页China Health Law

基　　金：2015年度教育部人文社会科学研究一般项目资助"医疗责任强制保险制度研究"(15YJCZH193);2016年广东省高等学校优秀青年教师培养计划项目"医疗纠纷预防与处理法律制度研究"(YQ2015131);广州医科大学2014年度校级科研项目"医疗责任强制保险制度研究"(2014C17)

摘　　要：《侵权责任法》第五十九条规定医疗机构须对药品缺陷承担不真正连带责任。该规定的立论基础并不妥当,其错误地将医疗机构定为药品销售者,与我国医疗体制改革之"公益性"方向相悖,违背"责任自负"原则。应按医疗机构对药品缺陷之控制力程度,将医疗机构的药品缺陷责任类型化地规定为四种:1.医疗机构对其生产的"医疗机构制剂"承担无过错责任;2.医疗机构对其药品采购、保管等行为承担过错推定责任;3.医疗机构对其诊疗服务过程中的用药行为承担过错责任;4.医疗机构对其不可控的生产者、销售者造成的药品缺陷不承担责任。The article 59 of Tort Liability Law regulate that medical institutions shall bear no really joint and several liability on drug defects.The theoretical foundation of the regulation is not appropriate.It is wrong that it regards medical institutions as drug sellers.This regulation is inconsistent with welfare direction in our health reform,and against the principle of＂responsibility conceited＂.It should be according to the medical institutions＇ controlling degree of drug defects.The medical institutions＇ drug defects liability can classify as four stereotype：1.medical institutions bear no-fault liability to pharmaceutical preparation of medical institution.2.medical institutions bear presumption of fault liability to the drug procurement and storage.3.medical institutions bear fault liability to the action of drug-using in the process of medical services.4.medical institutions bear no liability to the drug defects which are caused by drug producers and sellers.

关 键 词：医疗机构 药品缺陷 不真正连带责任 公益性 控制力 

分 类 号：D902[政治法律—法学理论]